DAVIS STEPHEN 4
4 · ACADIA PHARMACEUTICALS INC · Filed Mar 27, 2024
Insider Transaction Report
Form 4
DAVIS STEPHEN
EVP, CFO AND CBO
Transactions
- Award
Common Stock
2024-03-25+34,666→ 136,556 total - Sale
Common Stock
2024-03-27$17.90/sh−17,714$317,081→ 118,842 total - Award
Stock Option (Right to Buy)
2024-03-25+286,451→ 286,451 totalExercise: $17.84Exp: 2034-03-24→ Common Stock (286,451 underlying)
Footnotes (3)
- [F1]Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.